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Abstract
Background: The HOX11/TLX1 (hereafter referred to as HOX11) homeobox gene was originally identified at a
t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T cell acute
lymphoblastic leukemias (T-ALLs). We previously reported a predisposition to aberrant spindle assembly checkpoint
arrest and heightened incidences of chromosome missegregation in HOX11-overexpressing B lymphocytes
following exposure to spindle poisons. The purpose of the current study was to evaluate cell cycle specific
expression of HOX11.
Results: Cell cycle specific expression studies revealed a phosphorylated form of HOX11 detectable only in the
mitotic fraction of cells after treatment with inhibitors to arrest cells at different stages of the cell cycle. Mutational
analyses revealed phosphorylation on threonine-247 (Thr247), a conserved amino acid that defines the HOX11
gene family and is integral for the association with DNA binding elements. The effect of HOX11 phosphorylation
on its ability to modulate expression of the downstream target, cyclin B1, was tested. A HOX11 mutant in which
Thr247 was substituted with glutamic acid (HOX11 T247E), thereby mimicking a constitutively phosphorylated
HOX11 isoform, was unable to bind the cyclin B1 promoter or enhance levels of the cyclin B1 protein. Expression
of the wildtype HOX11 was associated with accelerated progression through the G2/M phase of the cell cycle,
impaired synchronization in prometaphase and reduced apoptosis whereas expression of the HOX11 T247E mutant
restored cell cycle kinetics, the spindle checkpoint and apoptosis.
Conclusions: Our results demonstrate that the transcriptional activity of HOX11 is regulated by phosphorylation of
Thr247 in a cell cycle-specific manner and that this phosphorylation modulates the expression of the target gene,
cyclin B1. Since it is likely that Thr247 phosphorylation regulates DNA binding activity to multiple HOX11 target
sequences, it is conceivable that phosphorylation functions to regulate the expression of HOX11 target genes
involved in the control of the mitotic spindle checkpoint.
Background
Dysregulated expression of homeobox genes is recog-
nized as a common mechanism in the pathogenesis of
leukemias [1]. Given their critical roles as transcription
factors capable of controlling cellular proliferation and
differentiation during embryogenesis, there has been
increasing interest in the possible role of homeobox
genes as potential proto-oncogenes when their regula-
tion goes awry. One such well-documented instance of
homeobox genes possessing oncogenic activity following
perturbation of their expression is the HOX11/TLX
gene family. To date, three family members of the
HOX11/TLX gene family are known: HOX11/TLX1,
HOX11L1/TLX2 and HOX11L2/TLX3. HOX11/TLX1
(hereafter referred to as HOX11) and HOX11L2/TLX3
have been reported to be frequent targets of aberrant
activation by chromosomal rearrangements in the
pathogenesis of T-lineage leukemias. In particular, the
HOX11 gene is rearranged in T-cell acute lymphoblastic
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t(7;10)(q35;q24) chromosomal translocations [2-4]. The
juxtaposition of the HOX11 gene downstream of either
the TCRa/δ or TCRb regulatory elements results in
aberrant expression of the homeobox gene in T lympho-
cytes, a cell type in which it is not typically expressed,
leading to T lymphocyte transformation and ultimately,
the development of T-ALL. Dysregulated HOX11
expression can also occur in the absence of chromo-
some translocations with aberrant expression being
reported in 3-5% of pediatric and up to 30% of adult
T-ALL cases [5-9]. Expression profiling of primary leu-
kemic lymphoblasts from HOX11
+ T-ALL patients was
indicative of leukemic arrest at an early cortical thymo-
cyte stage of T cell development [7], consistent with
immunophenotyping studies, which revealed primary
HOX11
+ T-ALL samples are predominantly TCRab
+
and TCRgδ
- [10]. Dysregulated HOX11 expression has
been reported in a subgroup of T-lymphoblastic lym-
phomas patients with favourable outcomes [11]. Addi-
tionally, retroviral transduction of fetal liver precursors
with HOX11 induced maturation arrest prior to the
CD4
+ CD8
+ double positive stage in fetal thymic organ
cultures [12]. The transforming capacity of HOX11
overexpression has also been verified in several in vitro
and in vivo studies. Overexpression of HOX11 by retro-
viral transduction was able to immortalize murine
hematopoietic and embryonic precursors, transform
murine bone marrow cells and lead to the de-differen-
tiation of the murine erythroleukemic cell line J2E in
vitro [13-15]. Additionally,w ed e v e l o p e dat r a n s g e n i c
mouse strain overexpressing HOX11 throughout B cell
development that developed spontaneous mature B cell
lymphomas with an extended latency [16,17].
The molecular mechanisms of action of HOX11 in
inducing a tumorigenic state remain unclear, although it
is thought that the transactivation of specific down-
stream genes by HOX11 is responsible, at least in part,
for cellular transformation. One-hybrid experiments
have elucidated three regions of the HOX11 oncopro-
tein which are important for optimal transactivation of
reporter constructs: an N-terminal glycine/proline rich
region, a C-terminal glutamine-rich region, and the
homeodomain [18]. A threonine residue at amino acid
position 247 (Thr247) (also referred to as position 47
within the homeodomain [19,20]), as opposed to the
valine or isoleucine residues typically encoded for in the
canonical homeodomains of other homeobox genes, is a
primary feature of all members of the HOX11/TLX gene
family [2]. In particular, this residue is thought to parti-
cipate in modulating the DNA-binding specificity of
HOX11. Instead of the canonical TAAT binding site
recognized by prototypical class I HOX proteins, the
threonine has been reported to impart a preferential
association with guanine nucleotides, altering the
HOX11 consensus recognition motif to TAAGTG [20].
One gene known to be targeted in a Thr247-dependent
fashion is aldehyde dehydrogenase 1 (Aldh1) [19,21].
A comprehensive structure-function analysis of the
HOX11 protein revealed that the transcriptional trans-
activation of genes specified by the Thr247 residue of
HOX11 was distinct from its immortalizing function, as
assayed by the ability to immortalize hematopoietic pre-
cursors and generate IL3-dependent myeloid-like cell
lines [19]. Mutation of the Thr247 residue to the cano-
nical amino acid, isoleucine, failed to abolish HOX11
transforming activity. Conversely, the PBX-interacting
motif (PIM), a domain involved in facilitating HOX11
interaction with its cognate PBX cofactors, was required
for immortalization. The PIM domain had previously
been shown to be unimportant in transcriptional trans-
activation of Aldh1 [22], but was essential in conferring
altered DNA-binding specificity of HOX11 to promoters
containing PBX-responsive sequences [23]. Thus, this
suggests a dual specificity of HOX11 target genes: those
dictated by the Thr247 residue within the homeodomain
and those dictated by HOX11 interaction with PBX1,
with the latter playing an important role in cellular
immortalization.
Several reports have implicated HOX11 in disruptions
of various cell cycle checkpoints. In Jurkat T cells,
HOX11 overexpression conferred an ability to aberrantly
bypass G2/M cell cycle checkpoint arrest induced by
gamma-irradiation [24]. High throughput analyses have
revealed that Jurkat T cells engineered to express
HOX11 exhibit aberrant expression of genes involved in
the regulation of the G1/S cell cycle checkpoint, includ-
ing E2F, c-Myc, and the cAMP-responsive element
binding protein (CREBP) [25]. An independent microar-
ray study performed on T-ALL cell lines overexpressing
HOX11 demonstrated elevated expression of the cell
cycle checkpoint regulators, NFKB2 and SMARCD3
[26]. Our and other groups have previously reported the
ability of HOX11 to promote bypass of mitotic check-
point arrest, leading to chromosome missegregation and
aneuploidy [27-29]. This abnormal mitotic checkpoint
regulation was correlated with abnormal expression of
several mitotic checkpoint regulators, including cyclin
B1. Collectively, these studies implicate disruption of the
cell cycle as an important biological effect of HOX11
overexpression, and may represent a critical mechanism
by which HOX11 elicits lymphoma.
Given the multiple defects in cell cycle regulation sub-
sequent to HOX11 overexpression in several different
cellular models, we investigated the expression of the
HOX11 protein at various stages of the cell cycle.
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HOX11 oncoprotein on the Thr247 residue, which was
specific to mitotic cells. The implications of this post-
translational modification with respects to cyclin B1
transactivation and mitotic spindle checkpoint were
explored.
Methods
Plasmid construction
FLAG-tagged wildtype and truncated HOX11 proteins
were generated by subcloning polymerase chain reac-
tion (PCR)-amplified fragments, corresponding to the
following HOX11 regions in frame with the sequence
encoding a FLAG peptide into the HindIII/NotI
restriction sites of the p3XFLAG-CMV-7.1 vector
(Invitrogen, Burlington, ON): HOX11Δ260 (amino
acids 1-260), HOX11Δ187 (amino acids 1-187) and
HOX11Δ106 (amino acids 1-106). HOX11 Thr247Ala,
Thr247Glu and Thr241Ala were generated using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA) prior to cloning as described above. Luci-
ferase reporter constructs were generated by subclon-
ing PCR-amplified fragments corresponding to the
following promoter regions upstream of the luciferase
reporter gene into the KpnI/HindIII restriction site of
t h ep G L 3v e c t o r( P r o m e g a ,M a d i s o n ,W I ) :C C N B 1 L -
LUC (contains -4902 to +21 relative to TSS of murine
cyclin B1 (CCNB1) gene) and CCNB1S-LUC (contains
-3310 to +21 relative to TSS of murine cyclin B1
(CCNB1) gene). All constructs were verified by DNA
sequencing.
Materials and cell lines
NIH 3T3 fibroblasts stably expressing the HOX11 onco-
protein were generated by transfection of NIH 3T3 cul-
tures with 3 μg MSCV-HOX11 plasmid constructs using
the Polyfect Transfection reagent (QIAGEN), and select-
ing with 800 μg/ml G418 (Sigma) for 14 days. Media
changes supplemented with fresh G418 were performed
every two days. Following 14 days of selection, 24 G418-
resistant colonies were picked, expanded and tested for
HOX11 positivity by Western immunoblotting with a
HOX11-specific antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). HOX11-3T3 fibroblasts were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% FCS, 2 mM L-glutamine and
1% penicillin/streptomycin. The T cell leukemia cell
lines Jurkat [30] and ALL-SIL [3] were maintained in
RPMI supplemented with 20% FCS, 2 mM L-glutamine
and 1% penicillin/streptomycin and maintained at a cell
density of 0.5-1.5 × 10
6 cells/ml. Relative levels of the
HOX11 protein in the different cell lines is shown in
Additional file 1, Figure S1.
Phosphorylation experiments
Nocodazole treatment was performed 24 hours after
seeding, on typically ~60-80% confluent cultures. Phos-
phoenriched lysates following nocodazole treatment
were generated using the PhosphoCruz Protein Purifica-
tion System (Santa Cruz) according to manufacturer’s
protocols. Staurosporine (Sigma) was added in conjunc-
tion with nocodazole at concentrations of 0, 20, 40, 60,
80 and 100 nM. A dose-response experiment using
staurosporine concentrations from 0.05 μMt o5 0 0μM
indicated drug concentrations did not impact cell viabi-
lity (Additional file 2, Figure S2). Recombinant protein
phosphatase 1 (PP1) catalytic subunit (Sigma) was added
in conjunction with nocodazole at concentrations of 1, 2
and 4 U/mL.
Co-immunoprecipitation and immunoblotting analysis
HOX11 co-immunoprecipitations were performed using
the Immunoprecipitation Kit with 1 μga n t i - H O X 1 1
monoclonal antibody, clone 1D7 (Santa Cruz) according
to manufacturer’s protocols. Immunoblotting analysis
was performed on SDS-separated proteins blotted to
nitrocellulose membrane, and probed at various dilu-
tions with a primary antibody recognizing HOX11
(1:2,000), FLAG (1:3,000), pSer (1:100), pThr (1:100),
PP1 (1:800), PP2A (1:2,000) and b-actin (1:2,000) for 4 h
at room temperature, followed by three washes with
PBST for 20 min each. Membranes were subsequently
incubated with either anti-mouse (1:10,000) or anti-rab-
bit (1:10,000) antibody conjugated to horseradish peroxi-
dase (HRP) for 1 h at room temperature. The anti-pSer
and anti-pThr antibodies were obtained from Anaspec,
the anti-FLAG antibody was obtained from Sigma. All
other antibodies were obtained from Santa Cruz Bio-
technologies (Santa Cruz, CA).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitations were performed using
the Chromatin Immunoprecipitation Kit (Upstate) and a
HOX11-specific antibody, clone 1D7, (Santa Cruz Bio-
technology, Santa Cruz, CA) according to manufac-
turer’s protocols. Primers used for ChIP PCR analyses
were:
CYCB1-1F: ACTTCATGCTATCAACCTCA; CYCB1-
1R: CCTCTTCTATAGAAGTGCCA;
CYCB1-2F: CCGCGTTAGTGTTACTGAAA; CYCB1-
2R: CAAAGATCTCTATTGCAACTCT; CYCB1-3F:
TGTAACCTCAACAATGAGGA; CYCB1-3R: ACAC
CATCCTGTGCTCTCTA;
CYCB1-4F: CAGTCTCCGGTGTGACATAA; CYCB1-
4R: GAGACAGGGTTTCTCTGTGT;
CYCB1-5F: AACAAGTTCCAGCCTCCACA; CYCB1-
5R: CCCATTACCAAGCTAGAGAG;
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6R: AAATGCCAATGGTCTCCCTG.
Luciferase assays
NIH 3T3 fibroblasts were seeded in 24-well dishes
24 hours prior to transfection. Cells were transfected
with 0.15 μgF L A G - H O X 1 1c o n s t r u c ta n d0 . 1 5μgp r o -
moter-reporter construct using the Polyfect transfection
reagent (QIAGEN). Each transfection was performed in
triplicate. Luciferase assays were performed using the
Luciferase Reagent Kit (Promega), according to manu-
facturer’s protocols. Briefly, cells were lysed by addition
of 200 μL CCNR lysis buffer, cleared by centrifugation
and 20 μL protein lysate was combined with 100 μL
luciferase reagent immediately prior to measurement in
the luminometer. For each sample, arbitrary luciferase
units were standardized to protein concentrations.
Electrophoretic mobility shift assay (EMSA) analysis
Nuclear extracts were derived from Jurkat cell lines sta-
bly expressing an empty Flag vector, Flag-HOX11-wt,
Flag-HOX11-T247A or Flag-HOX11-T247E. The oligo-
nucleotide probes derived from the CCNB1 promoter
and mutant probe were as follows: 5′-TCCATCCCAG-
TAATAAGTGTTTT-3′ and 5′-TCCATCCCAGTAA
GGGCCCTTTT-3′. Double-stranded oligonucleotide
probes were generated by annealing equimolar quanti-
ties of complementary oligonucleotide in 1× annealing
buffer (10 mM Tris-HCl, pH7.4, 50 mM NaCl, 1 mM
EDTA). Probes were incubated in 1× binding buffer
(10 mM Tris-HCl, pH7.6, 50 mM NaCl, 1 mM EDTA,
5%Glycerol) with 6 μg nuclear extract in a final volume
of 10 μl.The samples were incubated at room tempera-
ture for 30 min and resolved by electrophoresis in 6%
polyacrylamide nondenaturing gels in 0.5 × TBE at 100
voltage for 30 min. Following electrophoresis, the gels
were stained using an EMSA staining kit (Invitrogen,
Carlsbad,CA,USA) and photographed using a 300 nm
UV transilluminator.
Cell cycle analysis
Cells were synchronized at the G1/S checkpoint by cul-
turing for 16 h in 100 μg/ml aphidocolin, released into
S phase by feeding with fresh medium containing 10%
fetal calf serum for 4 h, arrested at G2/M by culturing
with 60 μg/ml genistein for 16 h, or trapped in mitosis
by using 400 μg/ml colchicine, 50 nM or 100 nM noco-
dazole (for ~50% accumulation or maximal accumula-
tion of cells in metaphase, respectively) or 3 μg/ml
cytochalasin B (for cytokinesis arrest following telo-
phase) for 16 h. Cell cycle distribution was determined
by propidium iodide staining and flow cytometry. For
each sample, 20,000 events were recorded.
Mitotic index
Cells were co-transfected with a pmax GFP-expressing
vector (Amaxa) and either an empty vector, a vector
expressing a wildtype HOX11 or a vector expressing the
HOX11Thr247Glu mutant. After 24 h, cells were syn-
chronized in mitosis by a 17 h exposure to colchicine
(40 ng/ml) or (10 ng/ml) and stained with Hoechst
33342 (10 μM) in 2% FCS/PBS in 37°C for 10 min.
Mitotic indexes of transfected cells were quantified
using immunofluorescent microscopy by scoring the
nuclear morphology of 200 GFP-expressing cells, with
bright-stained nuclei corresponding to prometaphase
arrested cells and dull or diffuse-stained nuclei corre-
sponding to cells that had escaped mitotic arrest. Cells
were viewed with an Axiovert 200 M epi-fluorescence
microscope using Axiovision Rel. 4.5 software (Carl
Zeiss, Toronto, ON, Canada). Each experiment was
replicated three times.
Apoptosis assays
Cell death was monitored by flow cytometric analysis of
cells stained by Annexin V (Biovision ) and propidium
iodine (PI) (Invitrogen), as per the manufacturer’s proto-
col. 30,000 cells were analyzed.
Results
HOX11 is phosphorylated during mitosis
To assess HOX11 expression levels at various stages of
the cell cycle, fibroblast cell lines stably expressing the
HOX11 oncoprotein (HOX11-3T3) were treated with
various inhibitors to induce cell cycle arrest at different
stages. HOX11-3T3 cells were synchronized at the G1/S
checkpoint by culturing for 16 h in aphidocolin and
released into S phase by feeding with fresh medium for
4 h, arrested at G2/M by culturing with genistein for
16 h, blocked in mitosis by exposure to colchicine or
nocodazole for 16 h or arrested during cytokinesis
following telophase with cytochalasin B for 16 h. While
no dramatic cell cycle-related fluctuations in HOX11
expression levels were detected by immunoblotting, we
observed the presence of a gel retarded cross-reacting
band when HOX11-3T3 cultures were treated with
colchicine or nocodazole (Figure 1A), but not following
treatment with the G2/M inhibitor, genistein or the
cytokinesis inhibitor, cytochalasin B. We hypothesized
that the additional band represented a post-translation-
ally modified version of the HOX11 peptide.
The lower mobility band was detected in a nocodazole
dose-dependent manner (Figure 1B) and in a time-
dependent manner (Figure 1C). Densitometry verified
that the presence of the higher molecular weight band
exhibited a linear correlation with the percentage of
cells arrested in the G2/M phase of the cell cycle
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Page 4 of 17Figure 1 HOX11 is Post-Translationally Modified During Mitosis in a Dose- and Time-Dependent Manner in Proportion to the
Percentage of Mitotic Cells. (A) Immunoblot analysis of HOX11 and b-actin levels in HOX11-3T3 cultures following treatment with 100 μg/ml
aphidocolin (aph), aphidocolin followed by release into fresh medium containing 10% fetal calf serum for 4 h (aph+4h), 60 μg/ml genistein
(gen), 400 μg/ml colchicine (colc), 100 nM nocodazole (noc) or 3 μg/ml cytochalasin B (cytoB). Flow cytometric profiles of DNA content and
percentage of cells containing a 4n complement of DNA are indicated. (B) Immunoblot analysis of HOX11 and b-actin expression in HOX11-3T3
cultures treated with varying doses of nocodazole for 17 hours (C) or with 50 nM nocodazole for varying times. Flow cytometric profiles of DNA
content and percentage of cells containing a 4n complement of DNA are indicated. Densitometric analysis of post-translationally modified band
intensity compared to the percentage of cells containing a 4n complement of DNA reveals a statistically significant linear relationship (R
2 > 0.9).
(D) Immunoblot analysis of HOX11 expression in sorted HOX11-3T3 subpopulations following Hoechst 33342 staining.
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the post-translational modification was specific to cells
in G2- or M-phase. To verify this, viable cell sorts of
Hoechst 33342 stained HOX11-3T3 cells were per-
formed using flow cytometry on asynchronous, genistein
and colchicine treated cultures, and subjected to immu-
noblot analysis (Figure 1D). Asynchronous cultures and
cultures in G1 (lanes 1 and 2, respectively) did not exhi-
bit a HOX11 post-translational modification. Similarly,
cells arrested at the G2/M boundary using genistein
(lane 3) also did not exhibit the HOX11 post-transla-
tional modification. As genistein induces arrest prior to
entry into M-phase, this suggested that the presence of
a 4n complement of DNA following DNA replication
alone was insufficient for the induction of the cross-
reacting band. Rather, only cells arrested in mitosis
(lane 4) following colchicine treatment exhibited the
higher molecular weight HOX11 peptide. Attempts to
perform HOX11 immunoblot for non-4n fractions of
these colchicine-treated cultures to eliminate the possi-
bility of a direct colchicine effect on the cultures were
attempted but failed owing to the limited number of
non-mitotic cells in these cultures. However, we believe
the effect was unlikely to be a direct effect of colchicine,
as the same phenomenon was seen with another mito-
sis-arresting drug, nocodazole. Furthermore, the effect
was not likely to be a general effect of genomic instabil-
ity caused by spindle poisons, as treatment with ethi-
dium bromide and acrylamide, agents capable of
inducing genomic instability but not mitotic arrest, had
no effect on eliciting the cross-reacting band (data not
shown). Collectively, these data provide evidence that
the post-translational change was specific to the mitotic
fraction. Interestingly, the unmodified HOX11 protein
was still readily detectable in this cell fraction. This may
be attributable to the cellular heterogeneity within this
fraction of cells which has been shown, using immunos-
tains for phosphohistone mitotic markers, to comprise
both mitotic cells and post-replicative, non-mitotic (G2)
cells [31]. Alternatively, this may reflect an incomplete
mechanism for post-translational modification of the
HOX11 peptide.
To test if this band represented a phosphorylated form
of HOX11, several assays were performed. First, immu-
noprecipitation was performed on HOX11-3T3 cultures
radiolabelled with 35S-gATP. We observed the presence
of a radiolabelled HOX11 isoform following induction
of mitotic arrest by nocodazole treatment, which was
abolished when co-treated with the non-specific kinase
inhibitor, staurosporine (Figure 2A). Secondly, lysates
were obtained from mitotically arrested cells, enriched
for phosphopeptides by immobilized metal affinity chro-
matography and subjected to HOX11 immunoblot.
While a doublet could be detected in non-enriched
lysates, only the higher molecular weight, lower mobility
band was detected in the phosphoenriched lysates (Fig-
ure 2B). Thirdly, total protein lysates were extracted
from nocodazole-treated HOX11-3T3 cells by repeated
freeze-thaw and subsequently incubated in vitro with
increasing amounts of alkaline phosphatase for 1 h at
37°C. Western immunoblotting of the entire reaction
confirmed the disappearance of the upper HOX11 band
upon alkaline phosphatase treatment (Figure 2C).
Fourthly, simultaneous treatment of HOX11-3T3 cul-
tures with a non-specific kinase inhibitor staurosporine,
in conjunction with nocodazole, abolished the modified
form of HOX11 in a dose-dependent manner (Figure
2D). And finally, given previous reports of direct inter-
actions of HOX11 with the catalytic subunits of protein
phosphatases PP1 and PP2A [24], we sought to explore
whether these protein phosphatases could play a role in
regulating the phosphorylated state of HOX11. Indeed,
we observed that recombinant PP1 catalytic subunit
(rPP1cs), when added in combination with nocodazole
to HOX11-3T3 cultures, very efficiently abrogated the
upper HOX11 band (Figure 2E). Collectively, this evi-
dence indicates that the lower mobility band represents
a phosphorylated form of HOX11.
HOX11 is phosphorylated on Threonine-247
HOX11 immunoblots, performed on anti-HOX11
immunoprecipitates of nocodazole-treated cultures, were
able to detect both the non-phosphorylated and phos-
phorylated HOX11 forms (Figure 3A). To ensure speci-
ficity, two different HOX11 antibodies were used for
these experiments: a mouse monoclonal antibody direc-
ted against the C-terminal domain of HOX11 was used
for the immunoprecipitation, whereas a rabbit polyclo-
nal antibody was used for immunoblotting. Additionally,
to determine which amino acid residues of HOX11 were
phosphorylated, immunoblots were performed using
anti-serine and anti-threonine. Only the anti-threonine
antibody yielded a signal at an appropriate molecular
weight corresponding to that of HOX11 following mito-
tic arrest (Figure 3A).
To identify the specific residue that was phosphory-
lated, several FLAG-tagged HOX11 mutants were gener-
ated (Figure 3B), and the ability of each mutant HOX11
protein to be phosphorylated was assessed. We observed
that a HOX11 mutant protein truncated at amino acid
260 (HOX11Δ260) was capable of being phosphorylated,
whereas a mutant protein truncated at amino acid 187
(HOXΔ187) was not, suggesting that the phosphorylated
residue likely resided between amino acids 187-260 (Fig-
ure 3C). Located within this region is the Thr247 resi-
due which is the defining feature of the HOX11 gene
family and is known to be integral to the association of
DNA binding elements containing the TAAGTG
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binding, we speculated that it would be a candidate resi-
due for phosphorylation and subsequent modulation of
transcriptional activity. To that end, we generated
HOX11 point mutants in which the Thr247 residue as
well as an adjacent Thr241 residue were mutated to ala-
nine, and assessed their ability to be phosphorylated.
We observed that mutation of the threonine residue at
amino acid 247 to an alanine (T247A) diminished
HOX11 phosphorylation following nocodazole treat-
ment, indicating that HOX11 was being phosphorylated
on threonine-247 (Figure 3D). Disruption of an adjacent
threonine on residue 241 did not have a similar effect.
Phosphorylation of HOX11 inhibits cyclin B1
transactivation
We next sought to determine whether the phosphoryla-
tion of HOX11 on the Thr247 residue played a role in
regulating expression of HOX11 downstream targets. To
accomplish this, we assessed the role of Thr247 phos-
phorylation on modulating the expression of a putative
HOX11 downstream target gene, cyclin B1 [29].
We first characterized the promoter region of the
cyclin B1 gene (CCNB1) with respect to potential
HOX11 binding sites. Chromatin immunoprecipitations
(ChIPs) were performed to detect direct HOX11 protein
association with putative promoter regions up to 5 kb
upstream of the transcription start site (TSS) of the
CCNB1 locus. Six different regions at intervals of 700-
1000 bp upstream of the TSS were analyzed. Whereas
there was minimal amplification of any of the six
regions in NIH 3T3 cells not expressing HOX11, we
detected HOX11-binding to four of six regions upstream
of the CCNB1 gene, with the strongest spanning a
region of DNA approximately -4500 to -4300 from the
TSS (Figure 4A). This region contains the TAAGTG
Figure 2 HOX11 is Phosphorylated During Mitosis. (A) HOX11 immunoprecipitates from 35S-gATP radiolabelled HOX11-3T3 cultures
following treatment with nocodazole (500 ng/ml) or nocodazole supplemented with staurosporine (50 μM). (B) Immunoblots of HOX11 and b-
actin protein levels in total and phosphoenriched fraction of nocodazole-treated lysates. (C) Immunoblot of HOX11 protein levels of untreated
and nocodazole-treated HOX11 lysates following incubation with various levels of alkaline phosphatase. Ponceau S staining demonstrating
exogenous addition of alkaline phosphatase to the in vitro enzymatic reaction. (D) Immunoblot of HOX11 protein levels following treatment with
nocodazole and 0.05, 0.5, 5.0 or 50 μM staurosporine. (E) Immunoblot of HOX11 protein levels following treatment with nocodazole in media
supplemented with 0-4 U of recombinant protein phosphatase 1 catalytic subunit (rPP1cs).
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Page 7 of 17Figure 3 HOX11 is Phosphorylated on Threonine-247. (A) Immunoblots of anti-HOX11 immunoprecipitates using anti-HOX11, anti-pThr and
anti-pSer antibodies. (B) Schematic diagram of expression constructs for FLAG-tagged HOX11 wildtype and mutant proteins. FLAG peptide,
PBX1-interacting domain (PIM domain), glutamine-rich stretch (QQxQQ) and homeodomain (HD) are noted. (C) Top Panel: HOX11 immunoblots
of wildtype FLAG-HOX11 and truncation mutants with and without nocodazole treatment. Middle Panel: Autoradiogram of in vitro
35S-gATP-
labelled FLAG-HOX11 species. NIH 3T3 cells transfected with wildtype FLAG-HOX11 or truncation mutations were pulsed with
35S-gATP either
with or without nocodazole. Anti-FLAG immunoprecipitates were obtained as described in the Materials and Methods. Bottom Panel: b-actin
immunoblot of wildtype FLAG-HOX11 and truncation mutants with and without nocodazole treatment. (D) Top Panel: HOX11 immunoblots
of wildtype FLAG-HOX11, T247A and T241A point mutants with and without nocodazole treatment. Middle Panel: Autoradiogram of in vitro
35S-gATP-labelled FLAG-HOX11 species. Bottom Panel: b-actin immunoblot of wildtype FLAG-HOX11 and point mutants with and without
nocodazole treatment.
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Page 8 of 17consensus site proposed by Tang and Breitman (1995)
to represent the HOX11 consensus binding sequence.
HOX11 association to this region was verified more rig-
orously by performing ChIP using an irrelevant anti-
CD21 isotype-matched control antibody. We were able
to reproduce the HOX11 association with the same
region of the CCNB1 promoter region, which was not
seen in cells lacking HOX11 or when we used the anti-
CD21 antibody (Figure 4B). EMSA analyses further sup-
ported binding of the HOX11 protein to the TAAGTG
target sequence (Additional file 3, Figure S3).
In addition to association with the promoter, we
assessed the ability of HOX11 to transcriptionally trans-
activate the CCNB1 promoter using luciferase reporter
Figure 4 HOX11 Binds to and Transcriptionally Modulates Expression of the Cyclin B1 (CCNB1) Promoter. (A) Chromatin
immunoprecipitation (ChIP) analysis using an anti-HOX11 antibody of six regions of the CCNB1 promoter region. (B) ChIP analysis of region 5 of
the CCNB1 promoter using an anti-HOX11 antibody and an irrelevant antibody control. (C) Promoter-reporter assays to determine HOX11
transactivation of the empty reporter vector (pGL3), the CCNB1 promoter containing the TAAGTG consensus site (CCNB1L-LUC, Long) and the
CCNB1 promoter missing the TAAGTG consensus site (CCNB1S-LUC, Short). Each bar represents the fold ratio of luciferase activity between HOX11-
and vector alone-transfected cultures for each promoter-reporter construct. The results are representative of three independent experiments.
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Page 9 of 17assays. CCNB1 promoter-luciferase reporter constructs
were generated which encompassed the putative HOX11
binding sequence, TAAGTG, in addition to one which
lacked the consensus sequence, designated CCNB1L-
LUC (Long) and CCNB1S-LUC (Short), respectively.
NIH3T3 cells were cotransfected with a wildtype
HOX11 cDNA and either an empty reporter construct
or constructs containing CCNB1S-LUC or CCNB1L-
LUC and luciferase activity was measured following
24 hours.
Transfection of the empty vector in the absence of
HOX11 showed background levels of luciferase activity
whereas cotransfection of the CCNB1S-LUC reporter
construct with a vector expressing the wild type HOX11
cDNA resulted in a three-fold increase in luciferase
activity (3.17-fold ± 0.49, p = 0.0029), demonstrating
that the CCNB1 regulatory elements in the presence of
HOX11 were active in NIH 3T3 cells. Cotransfection of
the CCNB1L-LUC construct with wild type HOX11 sig-
nificantly enhanced luciferase activity (5.61-fold ± 1.48,
p = 0.0024) (Figure 4C). Thus, HOX11 was able to mod-
ulate the levels of cyclin B1 expression through interac-
t i o nw i t hap u t a t i v eH O X 1 1b i n d i n gs i t es i t u a t e da t
approximately -4.5 kb upstream of the CCNB1 TSS.
Next, we investigated the effect on cyclin B1 transacti-
vation of a HOX11 point mutant in which the Thr247
was substituted with a glutamic acid (T247E), a fre-
quently used technique to partially mimic the negative
charge introduced by a phosphate group. This approach
has been used to simulate a phosphorylation-induced
alteration of DNA binding activity of other homeodo-
main-containing proteins [32,33]. Western immunoblot
analysis revealed low-level expression of cyclin B1 in
NIH 3T3 cells which was elevated in the presence of
HOX11. By contrast, the HOX11 T247E mutant was
unable to upregulate cyclin B1 expression (Figure 5A).
In accordance, ChIP analyses revealed a decreased asso-
ciation of the HOX11 T247E mutant with the CCNB1
promoter whereas the HOX11 T247A mutant showed
similar association with the CCNB1 promoter as wild
type HOX11 (Figure 5B). EMSA analyses further sup-
ported the binding of the HOX11 T247A mutant pro-
tein to the TAAGTG target site and no binding by the
HOX11 T247E mutant protein to the HOX11 consensus
site (Additional file 3, Figure S3). Additional luciferase
reporter assays comparing the transactivation of the
cyclin B1 promoter containing the TAAGTG HOX11
target sequence (CCNB1L) with the promoter lacking
the TAAGTG binding site (CCNB1S) in the presence or
absence of HOX11 indicated that the HOX11 protein
did not impact transactivation of the CCNB1 S promo-
ter (Figure 5C). In contrast, cells transfected with the
CCNB1L construct and HOX11 showed a statistically
significant increase in luciferase activity relative to cells
lacking the HOX11 protein. To assess the role of phos-
phorylation of the HOX11 protein in the regulation of
the cyclin B1 promoter, cells were cotransfected with
either CCNB1 S or CCNB1L in combination with either
the HOX11 T247E or HOX11 T247A mutants. Reporter
assays demonstrated an inability of the HOX11 T247E
mutant to transactivate either the long or short cyclin
B1 promoter and, surprisingly, showed significant
repression of transcription in the absence of the
TAAGTG sequence. The HOX11 T247A mutant was
fully functional with respect to transactivation of the
CCNB1 promoter, indicating that the fidelity of the
threonine residue was not the critical factor to HOX11-
mediated cyclin B1 upregulation, but rather, the loss of
function associated with modification to a glutamic acid
residue or following phosphorylation was likely due to a
steric interference with DNA binding.
Phosphorylation of HOX11 in clinically relevant T-cell
lines impacts the mitotic spindle checkpoint
Given the role of HOX11 in T lymphoid diseases, we
sought to determine whether this phenomenon could be
recapitulated in a T cell system. Using the T-ALL cell
line, ALL-SIL, which carries a t(10;14) translocation
concomitant with high levels of HOX11 expression [3]
and the TAL1
+ Jurkat T-ALL cell line [34] transfected
with the HOX11 cDNA, we observed a similar pattern
of HOX11 phosphorylation in T cell lines as was seen
in HOX11-expressing NIH 3T3 cells with the additional
low mobility band only being detected in cells exposed
to mitotic arresting agents (Figure 6A). Thus the phos-
phorylation of HOX11 following nocodazole or colchi-
cine treatment was reproducible in clinically relevant
T-cell lines and may be applicable to HOX11 disease
pathology.
We previously reported that dysregulated expression
of HOX11 contributed to the development of lymphoma
by allowing cells with missegregated chromosomes to
aberrantly bypass the spindle checkpoint although it
remained unclear whether this effect was dependent on
the Thr247 residue [28,29]. Therefore, to assess the role
of Thr247 phosphorylation in aberrant spindle check-
point bypass, Jurkat cells transfected with wild-type
H O X 1 lo rt h eT 2 4 7 Em u t a n tw e r ea r r e s t e di nm i t o s i s
with low dose nocodazole and the mitotic index com-
pared 17 hours later by immunofluorescence microscopy
by scoring nuclear morphology. Under these conditions,
cells expressing wild-type HOX11 exhibited abnormal
metaphase arrest with only 51% of cells showing nuclear
condensation whereas 73% and 74% of HOX11 T247E
or mock transfected cells, respectively, showed nuclear
condensation (Figure 6B, Additional file 4, Figure S4).
Moreover, time course studies revealed that HOX11-
expressing cells showed a premature decline in the
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Page 10 of 17mitotic index and improper progression through the
spindle checkpoint as compared with vector alone and
HOX11 T247E-expressing cells (Figure 6C). By 16
hours, more than 50% of HOX11-expressing cells had
escaped the mitotic arrest while 70% of vector control
and HOX11 T247E-expressing cells had remained
blocked in mitosis. Interestingly, even in the absence of
microtubule inhibitors and spindle checkpoint arrest,
HOX11-expressing cells showed accelerated progression
through mitosis as compared with mock and HOX11
T247E transfected cells (Figure 6D).
Of note, studies assessing cell death by flow cytometry
of annexin V and propidium iodide stained cells indi-
cated that Jurkat cells expressing wild-type HOX11
exhibited a reduced frequency of early-stage apoptotic
cells relative to mock and HOX11 T247E transfected
cells suggesting that HOX11 confers a survival advan-
tage to cells (Figure 6E). Combined, these data are con-
sistent with the hypothesis that HOX11 modulated
expression of cyclin B1 via phosphorylation of Thr247
and that cyclin B1, possibly in combination with other
HOX11 target genes, plays a role in the dysregulation of
Figure 5 Phosphorylation of HOX11 Inhibits Transactivation of the Cyclin B1 (CCNB1) Promoter. (A) Immunoblot of cyclin B1 levels
following transfection of FLAG-tagged HOX11 wildtype and mutant cDNA. Vector alone (va), wildtype HOX11 (wt) and HOX11 Thr247Glu (T247E)
are indicated. (B) Chromatin immunoprecipitation (ChIP) analysis using an anti-FLAG antibody on the CCNB1 promoter region following
transfection of FLAG-tagged HOX11 wildtype and mutant cDNA. (C) Promoter-reporter assays for activation of the CCNB1 promoter containing or
lacking the TAAGTG consensus site (CCNB1L-LUC, Long and CCNB1S-LUC, Short, respectively) following transfection of FLAG-tagged HOX11
wildtype and HOX11 T247A and HOX11 T247E mutant proteins. Each bar represents the fold ratio of luciferase activity between HOX11-deficient
and HOX11-expressing cultures for each promoter-reporter construct. Each transfection was performed on three independent cultures. The
results are representative of three independent experiments. Arbitrary luciferase units were standardized with Renilla.
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Page 11 of 17Figure 6 Phosphorylation of HOX11 During Mitosis in T-Cells is Associated with Aberrant Spindle Checkpoint Arrest and Reduced
Early Apoptotic Cells in Cultures Expressing Wild-Type HOX11 but not the HOX11 T247E Mutant. (A) Immunoblot analysis of HOX11 and
b-actin in ALL-SIL cells (upper panel) and Jurkat cells transiently transfected with HOX11 (lower panel). Cell lysates were prepared following
treatment with aphidocolin (aph) to arrest cells in G1, aphidocolin followed by a 4 h release into fresh medium (aph+4) to arrest cells in S
phase, genistein (gen) to arrest cells in G2/M and colchicines (colc), nocodazole (noc) or cytochalasin B (cytoB) to arrest cells in M. (A):
asynchronous culture. (B) Mitotic index of Jurkat cells transiently transfected with empty vector, wild type HOX11 or the HOX11 T247E mutant
then synchronized in mitosis with nocodazole. Nuclei were stained with Hoechst33342 (blue) and mitotic index determined by scoring
condensed nuclei. Results are representative of three independent experiments. Error bars indicate the standard deviation. (C) Mitotic index of
Jurkat cells transfected with wildtype and mutant HOX11. Nocodazole treated cells were harvested at 4-hour intervals and mitotic index
determined. (D) Dysregulated HOX11 expression accelerates transit through the G2/M phase of the cell cycle. Jurkat cells were transfected with
wildtype or mutant vectors. G1/S synchronized cells were released into the cell cycle then harvested at different time points and analyzed by
flow cytometry for 4n DNA content by PI-staining. (E) One or four days post transfection, Jurkat cells expressing vector alone, HOX11-wt or
HOX11-T247E cDNA were stained with Annexin V and PI and analyzed by flow cytometry to assess cell death. Percentages of early apoptotic
cells are indicate. The results are representative of three independent experiments.
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the M phase of the cell cycle. Furthermore, dysregulated
expression of cyclin B1 may confer a survival advantage
to cells with missegregated chromosomes.
Discussion
The multiple reports of deregulation of cell cycle check-
points associated with perturbations in HOX11 expres-
sion [24,25,27-29] prompted us to assess the cell cycle-
dependent expression of the HOX11 oncoprotein. In a
HOX11-3T3 fibroblast cell line in which the HOX11
gene was constitutively active, we observed a post-trans-
lational modification of HOX11 which correlated with
increased numbers of mitotic cells following treatment
with microtubule destabilizing compounds. Radiolabel-
ling studies using several HOX11 truncation and point
mutants revealed that this modification was the result of
phosphorylation of the HOX11 protein at Thr247 within
the homeodomain.
The 60-amino acid homeodomain is a conserved DNA
binding protein domain consisting of an N-terminal arm
and three a helices that are separated by a loop and a
turn. DNA binding of the homeodomain is mediated by
the third recognition helix and the N-terminal arm with
several conserved amino acids, including Arg3, Arg5,
Ile47, Gln50 and Asn51, playing a major role in DNA
recognition. Three of the residues, Arg5, Gln50 and
Asn51, are conserved in the homeodomains of HOX11
gene family members whereas the two other residues
are changed from Arg3 to Lys3 and Ile47 to Thr47.
Since both Arg3 and Lys3 have side chains with amine
groups this change likely does not affect DNA interac-
tions [20]. In contrast, Thr has both methyl and hydro-
xyl groups in its side chain while Ile contains only a
hydrophobic methyl group and this amino acid change
is associated with a change in the DNA recognition
sequence from TAATNN for canonical homeodomains
to TAAGTG for HOX11 gene family members [20].
Thus the Thr in position 247 in the HOX11 protein
plays a critical role in determining the specific DNA
base at the fourth position of the binding motif.
The data presented in this report indicated that phos-
phorylation of HOX11 on Thr247 limited the binding of
the HOX11 protein to the promoter region of cyclin B1.
Furthermore, HOX11 was phosphorylated only during
M phase of the cell cycle resulting in transient inhibition
of HOX11 DNA binding activity. Since Thr247 makes
specific contact with nucleic acids within the major
groove of the DNA double helix, phosphorylation of this
amino acid residue places a negative charge close to the
phosphates of DNA thereby interfering with DNA bind-
ing through electrostatic repulsion. Moreover, replace-
ment of Thr247 with glutamic acid to mimic
phosphorylation decreased DNA binding activity. Thus
phosphorylation of Thr247 provides a mechanism for
cells to inactivate target gene expression as cells enter
the M phase and reactivate expression as cells undergo
cytokinesis and re-enter the G1 phase of the cell cycle.
Phosphorylation represents a common mechanism in
regulating the DNA binding capacity of homeodomain-
containing transcription factors including the Drosophi-
lia homeodomain proteins Antennapaedia [35],
Engrailed-2 [33,36], Sex combs reduced (SCR) [37] and
Even-Skipped [38] and the mammalian homeodomain
proteins CDP/Cux [39], hSIX1 [40], the POU transcrip-
tion factors Oct-1, GHF-1 and Pit-1[41-43], the NK-like
homeodomain proteins, Csx/Nkx2.5 [44], and PRH/Hex
[45] and the clustered homeobox genes HOXA9 [46],
HOXA10 [47-50], HOXB6 [51] and HOXB7 [52]. In
some cases, as is the case with HOX11, phosphorylation
occurs at conserved sites located within the homeodo-
main affecting target gene expression and transforming
potential. In particular, the HOXA9 and HOXA10
homeobox genes are frequently over-expressed in acute
myeloid leukemias (AMLs). HOXA9 has been reported
to be phosphorylated on serine, threonine and tyrosine
residues within its homeodomain with phosphorylation
correlating with decreased transforming capability in
myeloid and murine bone marrow cells [46,53]. Two
conserved tyrosine residues in the homeodomain of
HOXA10 are phosphorylated during cytokine induced
differentiation of myeloid progenitors resulting in
decreased HOXA10 binding affinity for regulatory ele-
ments of myeloid-specific genes [47-49,54]. The proline-
rich homeodomain protein (PRH)/HEX functions early
in embryonic vascular and hematopoietic development
[55] and as an oncoprotein in T cells [56-58]. Both
HOX11 and PRH/HEX are members of the NK-like
subclass of homeodomain proteins. Similar to HOX11,
PRH has a proline-rich region in the amino terminus of
the protein which is involved in its interaction with a
variety of proteins including Groucho/TLE and tran-
scription factor eIF-4E (eukaryotic initiation factor 4E)
[59-64]. PRH is phosphorylated at two conserved amino
acids within the homeodomain with phosphorylation
inhibiting DNA binding and transcriptional repression
of target genes [45]. In other cases, cell cycle specific
phosphorylation of homeodomain proteins effects cell
cycle progression [41,42,65-67]. For example, Six1 con-
tributes to the regulation of the G2/M checkpoint with
phosphorylation during interphase and mitosis inhibiting
DNA binding activity [40]. Moreover, the POU tran-
scription factors GHF-1 and Oct-1 undergo mitosis-spe-
cific phosphorylation on amino acids within the
homeodomain with phosphorylation correlating with in
vitro and in vivo inhibition of DNA binding activity
[41,42,66]. Thus M-phase specific phosphorylation may
represent an important mechanism for regulating gene
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cell cycle.
We observed that the transcriptional activity of the
HOX11 oncoprotein was modulated by phosphorylation
of the Thr247 residue. Specifically, the ability of HOX11
to modulate levels of cyclin B1 expression was impaired
by a form of HOX11 that contained an acid amino acid
substitution at Thr247 that mimicked a constitutively
phosphorylated HOX11. Moreover, we observed that the
Thr247-dependent upregulation of cyclin B1 was asso-
ciated with dysfunction of the spindle assembly check-
point. In this respect, our findings are consistent with
previous studies in delineating an uncoupling between
genes targeted by the Thr247 residue associated with
deregulating the spindle assembly checkpoint and
HOX11 target genes involved in cell immortalization
[19]. These data, therefore, reaffirm the belief that
HOX11 target genes fall into two groups: (1) those regu-
lated via Thr247-directed interactions with promoter
regions containing the HOX11 consensus recognition
sequence TAAGTG, and (2) those regulated through
association of promoter regions with HOX11-PBX het-
erodimers [19].
O nt h eb a s i so ft h eD N Ab i n d i n ga c t i v i t yo ft h e
HOX11 homeodomain and its ability to transactivate
reporter gene expression through both TATA-contain-
ing and TATA-less promoters [19], it has long been
thought that HOX11 functions as a transcriptional regu-
lator. Moreover, several putative HOX11 gene targets,
including Aldh1a1, Wt, c-kit and Vegfc [21,68-70], have
been identified. However, with the exception of its asso-
ciation with its own promoter, the binding of HOX11 to
the promoter region of target genes has not been con-
vincingly demonstrated and thus the mechanism of
HOX11 homeodomain dependent transcriptional regula-
tion of gene targets remains to be elucidated. The
inability to demonstrate target DNA sequence binding
has led to speculation that HOX11 regulates gene
expression through specific protein-protein interactions
with cofactors such as PBX [23], Meis [71] or Groucho/
transducin-like Enhancer of split (Gro/TLE) [63] and
components of the basal transcriptional machinery,
including CTF1 [72]. However, systematic mutational
analysis indicated that regulation of Aldh1a1 and the
oncogenic properties of HOX11 are both dependent on
an intact homeodomain [19,22] suggesting that DNA
binding is required for HOX11 target gene regulation.
The studies described herein help clarify the mechanism
of HOX11 mediated transcriptional regulation in that
they provide the first evidence of the direct binding of
HOX11 to a target TAAGTG sequence located more
than 4 kb upstream of the cyclin B1 transcription initia-
tion site. This is consistent with a model in which the
homeodomain of HOX11 recognizes and binds to target
DNA sequences in the distal promoter region and, once
recruited, modulates transcriptional activity by folding
or looping back and interacting with the basal transcrip-
tional machinery.
The physiological relevance of HOX11 phosphoryla-
tion was demonstrated with respect to its effects on
cyclin B1 expression and spindle assembly checkpoint
regulation. Expression of wild type HOX11 increased
expression of cyclin B1 and this elevated expression was
associated with a reduction in transition time through
the G2/M checkpoint, a reduced mitotic index and a
reduction in the frequency of early apoptotic cells. In
contrast, the threonine-to-glutamic acid substitution
mutant resulted in a return to normal levels of cyclin
B1 expression, cell cycle kinetics, mitotic index and fre-
quency of early apoptotic cells.
Cyclin B1 is the regulatory subunit of cyclin depen-
dent kinase (CDK1). The CDK1/cyclin B1 complex is
critical for the control of G2/M transition as it controls
the centrosome cycle and the onset of mitosis (reviewed
by [73]. The CDK1/cyclin B1 complex phosphorylates
numerous target proteins during G2 and early mitosis
triggering multiple processes including centrosome
separation, nuclear envelope breakdown and chromo-
some condensation. Transition through metaphase is
regulated by the spindle assembly checkpoint which
ensures bipolar attachment of all chromosomes to the
mitotic spindle. Once all chromosomes are aligned at
the metaphase plate, chromosome segregation is
mediated by the anaphase promoting complex/cyclo-
some (APC/C), an E3 ubiquitin ligase responsible for
targeting cyclins, including cyclin B1, for degradation.
Degradation of cyclin B1 and the associated inactivation
of the CDK/cyclin B1 complex allows chromatid separa-
tion, chromosome decondensation, reformation of the
nuclear envelope and cytokinesis. Given that the degra-
dation of cyclin B1 is critical for entry of cycling cells
into anaphase it was surprising that cells expressing the
nonphosphorylatable HOX11 T247A mutant and thus
unable to downregulate cyclin B1 expression appear to
undergo normal mitosis and retain cellular viability. It is
possible that other HOX11 target genes involved in the
shuttling of cyclin B1 between the nucleus and cyto-
plasm, its phosphorylation-dependent import and accu-
mulation in the nucleus at prophase or its degradation
during the metaphase to anaphase transition may also
be regulated in a Thr247 phosphorylation specific man-
ner. Consequently the extended expression of cyclin B1
into anaphase in cells expressing the HOX11 T247A
mutant might be countered by these target genes that
are no longer regulated at the anaphase transition. In
support of this, expression profiling studies undertaken
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of the APC are deregulated in HOX11transgenic B cells
although studies have not yet been initiated to deter-
mine whether these HOX11 target genes are also regu-
lated by Thr247 phosphorylation.
Given the essential role of cyclin B1 in the regulation
of the G2/M cell cycle checkpoint, it is not surprising
that deregulated cyclin B1 expression has been linked to
malignant transformation [73]. In normal cells, expres-
sion of cyclin B1 begins at S phase with protein accu-
mulation reaching maximal levels at the onset of
mitosis. Cyclin B1 is subsequently rapidly degraded at
the metaphase-anaphase transition. In primary tumour
tissues and leukemia cell lines, accumulation of cyclin
B1 is detected in the G1 phase [74-76]. In addition, ele-
vated cyclin B1 has been reported in numerous cancers
including gastric [77], colorectal [78], head and neck
squamous cell carcinoma [79,80] and non-small-cell
lung cancer [81,82]. Deregulated cyclin B1 expression is
associated with poor prognosis [78,80,82], histological
grade of differentiation and vascular invasion [81]. Ele-
vated cyclin B1 expression often precedes tumour
immortalization and aneuploidy suggesting that deregu-
lated expression of cyclin B1 is an early tumorigenic
event [83,84]. Since HOX11-expressing malignancies are
associated with deregulation of the G2/M cell cycle
checkpoint [24-27] and chromosome missegregation
[28,29], pharmacological inhibition of cyclin B1 could
provide a specific intervention for the treatment of
T-ALL.
Conclusions
Our results demonstrate that the transcriptional activity
of HOX11 is regulated by temporal phosphorylation of
Thr247 in a cell cycle-specific manner and that this
phosphorylation modulates the expression of the target
gene, cyclin B1. Since it is likely that Thr247 phosphory-
lation regulates DNA binding activity to multiple
HOX11 target sequences, it is conceivable that phos-
phorylation functions to regulate the expression of
HOX11 target genes involved in the control of the mito-
tic spindle checkpoint.
Additional material
Additional file 1: Expression of HOX11 in Cell Lines. Immunoblot
analysis of HOX11 and b-actin showing similar levels of HOX11
expression in cell lines. Lane 1: 3T3-vector alone, lane 2: 3T3-HOX11, lane
3: K3P, lane 4: ALL-SIL, lane 5: Jurkat-vector alone, lane 6: Jurkat-HOX11-
wt, lane 7 Jurkat-HOX11-T247E, lane 8: Jurkat-HOX11-T247A.
Additional file 2: Titration of staurosporin showing HOX11
phosphorylation over a range of staurosporin concentrations.
HOX11-3T3 cultures were supplemented with varying concentrations of
staurosporin ranging from 0 mM to 500 mM in the presence or absence
of 500 nM nocodazole.
Additional file 3: EMSA analysis showing binding of the wild type
HOX11and HOX11 T247A mutant proteins to the TAAGTG target
sequence located ~4.5 kb upstream of the translation start site.
Double-stranded oligonucleotide targets were incubated with nuclear
extracts derived from Jurkat cell lines stably expressing an empty flag-
vector, flag-HOX11-wt, flag-HOX11-T247 or flag-HOX11-T247E. Reactions
included a 23 oligonucleotide target derived from sequences located
~4.5 kb upstream of the cyclin B1 translation start site or a mutant
target. Other than the TAAGTG HOX11 binding site, the target sequence
does not contain known transcription factor binding sites. EMSA analyses
showed binding to the target oligonucleotide sequence by specific
factors present in Jurkat cells stably expressing the wild type HOX11
protein and HOX11 T247A mutant protein (left panel, lanes 4-7) but no
binding of factors present in Jurkat cells stably expressing the
HOX11T247E mutant protein (left panel, lanes 8-9). Mutation of the
TAAGTG HOX11 binding site in target oligonucleotides prevented factor
binding (right panel, lanes 4-7). The presence of the wild type HOX11
protein and the mutant HOX11T247A protein within the factor complex
was confirmed by supershift analysis using an anti-flag antibody. Lane 1:
free probe. Lane 2: probe + flag-vector. Lane 3: probe + flag-vector +
anti-flag antibody. Lane 4: probe + flag-HOX11-wt. Lane 5: probe + flag-
HOX11-wt + anti-flag antibody. Lane 6: probe + flag-HOX11-T247A. Lane
7: probe + flag-HOX11-T247A + anti-flag antibody. Lane 8: probe + flag-
HOX11-T247E. Lane 9, probe + flag-HOX11-T247E+ anti-Flag antibody.
Additional file 4: Enhanced viability of Jurkat cells stably expressing
HOX11. Jurkat cells stably expressing an empty flag-vector, flag-HOX11-
wt or flag-HOX11-T247E cDNA were subjected to mock Amaxa
nucleofection in Solution V using program X-001. Cells were stained with
Annexin V and propidium iodide (PI) and analyzed by flow cytometry to
assess cell death prior to nucleofection and 2 days post nucleofection.
Numbers shown in lower right quadrants indicate percentages of early
apoptotic cells. The results are representative of three independent
experiments.
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